Agile_Logo-color on white.jpg
Agile Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
March 12, 2018 16:15 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., March 12, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company, today reported financial results for the three months and year ended...
Agile_Logo-color on white.jpg
Agile Therapeutics to Host First Analyst Day on October 10, 2017
October 02, 2017 07:30 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that the Company will host its first Analyst Day on Tuesday,...
Agile_Logo-color on white.jpg
Agile Therapeutics to Present Additional Phase 3 Data at the North American Forum on Family Planning Annual Meeting
September 28, 2017 07:45 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that an abstract based on the Phase 3 SECURE trial of its...
Agile_Logo-color on white.jpg
Agile Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
September 14, 2017 07:45 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s health specialty pharmaceutical company, announced today that Al Altomari, Chairman and CEO,...
Agile_Logo-color on white.jpg
Agile Therapeutics to Present Additional Phase 3 Data at the 73rd Annual Congress of the American Society for Reproductive Medicine
September 07, 2017 07:50 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that an abstract presenting data from the Phase 3 SECURE...
Agile_Logo-color on white.jpg
Agile Therapeutics Reports Second Quarter 2017 Financial Results
July 28, 2017 07:30 ET | Agile Therapeutics, Inc.
Cash Expected to Fund Operations into Q2 2018 FDA Assigns Prescription Drug User Fee Act (PDUFA) Goal Date of December 26, 2017 PRINCETON, N.J., July 28, 2017 (GLOBE NEWSWIRE) -- Agile...
Agile_Logo-color on white.jpg
Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®
July 27, 2017 16:11 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced that the U.S. Food and Drug Administration...
Agile_Logo-color on white.jpg
Agile Therapeutics to Present Additional Phase 3 Data at the 2017 Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and Gynecologists
May 03, 2017 16:15 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company today announced that data from its Phase 3 SECURE study will be presented at...
Agile_Logo-color on white.jpg
Agile Therapeutics Announces Results of its Pre-Submission Meeting with FDA
April 11, 2017 07:00 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., April 11, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s healthcare company, today announced it has received the final meeting minutes from its recent...
Agile_Logo-color on white.jpg
Agile Therapeutics Announces a Poster Presentation of its SECURE Phase 3 Study at the Contraceptive Technology 2017 Conference
March 16, 2017 16:30 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., March 16, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s healthcare company, announced a poster presentation of data from the SECURE Phase 3 clinical...